Charles Schwab’s Thermo Fisher Scientific TMO Stock Holding History

Charles Schwab’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.44B	Buy	2,934,842 +91,188	+3%	+$49.5M	0.22%	80
2025 Q4	$1.65B	Sell	2,843,654 -10,794	-0.4%	-$6.1M	0.26%	67
2025 Q3	$1.38B	Sell	2,854,448 -146,114	-5%	-$68M	0.22%	74
2025 Q2	$1.22B	Buy	3,000,562 +75,508	+3%	+$31.6M	0.21%	82
2025 Q1	$1.46B	Buy	2,925,054 +114,926	+4%	+$62.2M	0.27%	64
2024 Q4	$1.46B	Buy	2,810,128 +366,191	+15%	+$201M	0.27%	59
2024 Q3	$1.51B	Buy	2,443,937 +61,017	+3%	+$36.1M	0.29%	56
2024 Q2	$1.32B	Buy	2,382,920 +34,501	+1%	+$19.8M	0.25%	71
2024 Q1	$1.36B	Buy	2,348,419 +71,153	+3%	+$39.9M	0.32%	54
2023 Q4	$1.21B	Buy	2,277,266 +92,338	+4%	+$44.7M	0.31%	60
2023 Q3	$1.11B	Buy	2,184,928 +8,672	+0.4%	+$4.62M	0.32%	55
2023 Q2	$1.14B	Sell	2,176,256 -15,340	-0.7%	-$8.28M	0.32%	53
2023 Q1	$1.26B	Buy	2,191,596 +38,612	+2%	+$21.8M	0.38%	41
2022 Q4	$1.19B	Buy	2,152,984 +62,495	+3%	+$33.1M	0.38%	45
2022 Q3	$1.06B	Buy	2,090,489 +30,253	+1%	+$16.9M	0.38%	49
2022 Q2	$1.12B	Buy	2,060,236 +14,667	+0.7%	+$8.07M	0.39%	47
2022 Q1	$1.21B	Buy	2,045,569 +32,043	+2%	+$18.4M	0.36%	45
2021 Q4	$1.34B	Buy	2,013,526 +47,206	+2%	+$29.5M	0.4%	42
2021 Q3	$1.12B	Buy	1,966,320 +21,189	+1%	+$11.6M	0.37%	53
2021 Q2	$981M	Buy	1,945,131 +47,449	+3%	+$22.4M	0.33%	60
2021 Q1	$866M	Buy	1,897,682 +14,398	+0.8%	+$6.87M	0.32%	61
2020 Q4	$877M	Sell	1,883,284 -32,193	-2%	-$15.1M	0.35%	53
2020 Q3	$846M	Buy	1,915,477 +48,950	+3%	+$20.2M	0.39%	50
2020 Q2	$676M	Sell	1,866,527 -10,874	-0.6%	-$3.64M	0.33%	56
2020 Q1	$532M	Buy	1,877,401 +5,459	+0.3%	+$1.72M	0.31%	63
2019 Q4	$608M	Buy	1,871,942 +26,617	+1%	+$8.07M	0.33%	52
2019 Q3	$537M	Buy	1,845,325 +48,566	+3%	+$13.9M	0.32%	56
2019 Q2	$528M	Buy	1,796,759 +40,204	+2%	+$11.1M	0.32%	55
2019 Q1	$481M	Buy	1,756,555 +119,201	+7%	+$29.7M	0.31%	61
2018 Q4	$366M	Buy	1,637,354 +42,021	+3%	+$9.86M	0.28%	65
2018 Q3	$389M	Buy	1,595,333 +28,770	+2%	+$6.62M	0.26%	70
2018 Q2	$324M	Buy	1,566,563 +46,519	+3%	+$9.87M	0.24%	74
2018 Q1	$314M	Sell	1,520,044 -8,536	-0.6%	-$1.79M	0.24%	70
2017 Q4	$290M	Sell	1,528,580 -42,085	-3%	-$8.06M	0.23%	74
2017 Q3	$297M	Buy	1,570,665 +33,606	+2%	+$6.09M	0.26%	63
2017 Q2	$268M	Buy	1,537,059 +135,068	+10%	+$22.7M	0.25%	66
2017 Q1	$215M	Buy	1,401,991 +48,941	+4%	+$7.48M	0.22%	80
2016 Q4	$191M	Buy	1,353,050 +35,121	+3%	+$5.18M	0.21%	84
2016 Q3	$210M	Buy	1,317,929 +49,886	+4%	+$7.69M	0.25%	66
2016 Q2	$187M	Buy	1,268,043 +159,131	+14%	+$23.5M	0.23%	70
2016 Q1	$157M	Buy	1,108,912 +57,709	+5%	+$7.73M	0.21%	89
2015 Q4	$149M	Buy	1,051,203 +39,952	+4%	+$5.33M	0.2%	93
2015 Q3	$124M	Buy	1,011,251 +24,034	+2%	+$3.13M	0.18%	109
2015 Q2	$128M	Buy	987,217 +13,215	+1%	+$1.72M	0.18%	109
2015 Q1	$131M	Buy	974,002 +40,944	+4%	+$5.28M	0.18%	108
2014 Q4	$117M	Buy	933,058 +47,190	+5%	+$5.74M	0.18%	118
2014 Q3	$108M	Buy	885,868 +21,625	+3%	+$2.63M	0.18%	118
2014 Q2	$102M	Sell	864,243 -187,373	-18%	-$22.1M	0.17%	117
2014 Q1	$126M	Buy	1,051,616 +114,316	+12%	+$13.6M	0.23%	84
2013 Q4	$104M	Sell	937,300 -682,909	-42%	-$67.9M	0.2%	105
2013 Q3	$150M	Sell	1,620,209 -318,892	-16%	-$28.8M	0.31%	63
2013 Q2	$167M	Buy	+1,939,101	New	+$161M	0.37%	47

Other funds holding TMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Charles Schwab's TMO Position: Q1 2026 in Review

Charles Schwab increased its Thermo Fisher Scientific (TMO) stake by 3.2% in Q1 2026, buying an estimated $49.5M and bringing the position to 2,934,842 shares worth $1.44B. The position accounts for 0.22% of the portfolio, ranked #80.

Charles Schwab first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.65B in Q4 2025. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

Charles Schwab held 2,934,842 shares of Thermo Fisher Scientific worth $1.44B as of Q1 2026.
Charles Schwab bought 91,188 Thermo Fisher Scientific shares in Q1 2026, an estimated $49.5M.
Thermo Fisher Scientific made up 0.22% of Charles Schwab's portfolio in Q1 2026, its #80 holding.
Charles Schwab first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
Charles Schwab's Thermo Fisher Scientific position peaked at $1.65B in Q4 2025.
2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.